
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
Ensuring that materials have optimal critical quality attributes for the required formulations is crucial.
Jean-Philippe Talmon, chief procurement officer at Capsugel, shares best practices, for both natural and synthetic materials.
Download Pharmaceutical Technology’s
.
about 10 years ago
Extending QMS to Contract Partnersabout 10 years ago
Investigation Effectiveness Drives Human Performance Excellenceabout 10 years ago
Is Global Regulatory Gridlock Slowing Modernization?about 10 years ago
Paperless Batch Records for the Massesabout 10 years ago
Microbiological Testing: Time is of the Essence





